Activation of BA receptors, including the nuclear hormone receptor farnesoid X receptor (FXR) and the membrane-bound G protein-coupled BA receptor 1 (GPBAR1, also known as TGR5), holds promise as a therapeutic approach to prevent DKD (Wang et al. Here, GPBAR1 is linked to diabetic kidney disease.